Acurx Pharmaceuticals Inc (ACXP) Stock Price, Quote & News

Company Profile

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant st...

Industry: Biotechnology

Sector: Healthcare

Phone: 917 533 1469

Website: www.acurxpharma.com

Address:

259 Liberty Avenue, Staten Island, United States

Vikingsstrade Oct. 3 at 5:51 PM

$OST $MKZR $CLDI $ACXP Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve!

0 · Reply

knonaogn Oct. 3 at 4:03 PM

$ACXP Soon 60 to 180

0 · Reply

WallStVisions Oct. 3 at 1:06 PM

GIPR is the kind of play that only makes sense before it takes off. Real estate backed. Undervalued. And now with serious whispers of a crypto treasury strategy that could turn this into the next multi-sector rocket. 20x–50x isn’t hype it’s math if they execute. $ZVSA $IMUX $GENE $BTTX $ACXP

0 · Reply

NotBornYesterday Oct. 2 at 11:00 PM

Who do you think? Management uses $ACXP shareholders money to pay the Wainwright whorehouse underwriting fee everytime they dilute the shit out of the stock.

0 · Reply

1Spartantrade1 Oct. 2 at 6:25 PM

Massive merger news 3 days ago on NITO! NITO has a low share count like TTNP (BTTC) does. TTNP ran 400% today. Can NITO also run 400%? Make sure to take profits. Lets see if NITO halts up today when people realize. $CLDI $ACXP $NIVF $FLGC

0 · Reply

ChicagoJoe20 Oct. 1 at 6:44 PM

$ACXP FU bacteria!

0 · Reply

knonaogn Oct. 1 at 5:31 PM

$ACXP $ACXP Acurx Pharmaceuticals Price Target Maintained With a $31.00/Share by HC Wainwright & Co

0 · Reply

NotBornYesterday Oct. 1 at 4:13 PM

$ACXP Good thing Wainwright's been accurate on the -90% move.

1 · Reply

ScrubaDubs Oct. 1 at 3:07 PM

$ACXP thar she blows

0 · Reply

prismmarketview Oct. 1 at 2:49 PM

$ACXP received a positive EMA opinion on its pediatric plan for treating C. difficile infections, clearing the path to Phase 3 trials in Europe. With FDA Fast Track & QIDP designations already in place, Acurx is advancing toward late-stage development. https://prismmarketview.com/acurx-gains-positive-ema-opinion-on-pediatric-plan-for-c-difficile-infection-treatment/

0 · Reply

Acurx Announces Positive Opinion from EMA on Pediatric Investigation Plan for Ibezapolstat Use in Children with C. difficile Infection

Sep 3, 2025, 7:01 AM EDT - 4 weeks ago

Acurx Pharmaceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Closing Bid Price and Stockholder Equity Rules

Aug 12, 2025, 10:13 AM EDT - 7 weeks ago

Acurx Pharmaceuticals, Inc. (ACXP) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 7:01 AM EDT - 7 weeks ago

Acurx Pharmaceuticals, Inc. Reports Second Quarter Results and Provides Business Update

Jul 31, 2025, 9:25 AM EDT - 2 months ago

Acurx Pharmaceuticals, Inc. Announces Reverse Stock Split

Jul 24, 2025, 7:01 AM EDT - 2 months ago

Acurx Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 12, 2025 Conference Call and Provide Business Update

Jun 17, 2025, 9:47 PM EDT - 3 months ago

Acurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross Proceeds

Jun 17, 2025, 7:01 AM EDT - 3 months ago

Acurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI

Jun 9, 2025, 7:30 AM EDT - 4 months ago

Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Federation of American Societies for Experimental Biology Scientific Conference

May 13, 2025, 1:59 PM EDT - 5 months ago

Acurx Pharmaceuticals, Inc. (ACXP) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:01 AM EDT - 5 months ago

Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update

Apr 30, 2025, 7:30 AM EDT - 5 months ago

Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update

Apr 28, 2025, 7:30 AM EDT - 5 months ago

Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

Apr 17, 2025, 7:30 AM EDT - 6 months ago

Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors

Mar 18, 2025, 9:44 AM EDT - 7 months ago

Acurx Pharmaceuticals, Inc. (ACXP) Q4 2024 Earnings Call Transcript

Mar 18, 2025, 7:01 AM EDT - 7 months ago

Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Mar 10, 2025, 4:30 PM EDT - 7 months ago

Acurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct Offering

Mar 7, 2025, 8:00 AM EST - 7 months ago

Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering

Mar 3, 2025, 8:00 AM EST - 7 months ago

Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics

Feb 28, 2025, 8:00 AM EST - 7 months ago

Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update

Feb 24, 2025, 8:00 AM EST - 7 months ago

Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI

Feb 19, 2025, 8:00 AM EST - 8 months ago

JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors

Jan 7, 2025, 5:00 PM EST - 9 months ago

Acurx Pharmaceuticals, Inc. Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 6, 2025, 5:35 PM EST - 9 months ago

Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 6, 2025, 8:30 AM EST - 9 months ago

Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)

Dec 11, 2024, 11:00 AM EST - 10 months ago

Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025

Dec 9, 2024, 8:00 AM EST - 10 months ago

Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA Communications

Nov 20, 2024, 10:53 AM EST - 11 months ago

Acurx Pharmaceuticals to add up to $1 million in bitcoin for treasury reserve, following MicroStrategy's playbook

Nov 20, 2024, 7:01 AM EST - 11 months ago

Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset

Nov 18, 2024, 7:00 AM EST - 11 months ago

Acurx Sponsored and Participated in the Peggy Lillis Foundation Inaugural CDI Scientific Symposium and Presented Ibezapolstat Ph2b Clinical Data Update

Nov 13, 2024, 11:43 AM EST - 11 months ago

Acurx Pharmaceuticals, Inc. (ACXP) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 7:00 AM EST - 11 months ago

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update

Oct 21, 2024, 10:07 AM EDT - 1 year ago

Acurx Ready To Expand Pipeline With Anthrax Treatment

Oct 21, 2024, 7:00 AM EDT - 1 year ago

Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference

Oct 17, 2024, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Announces Participation at The Spartan Capital Investor Conference to Showcase Growth Companies and Foster High-Level Investor Engagement

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024

Oct 14, 2024, 1:00 PM EDT - 1 year ago

New to the Street Resigns Acurx Pharmaceuticals, Inc. to Multi-Platform Media Series Featuring Broadcast Television, Earned Media, and Outdoor Advertising Support

Oct 11, 2024, 10:50 AM EDT - 1 year ago

New to the Street Announces Exclusive Bloomberg Lineup for October 11 at 6:30 PM EST

Sep 26, 2024, 7:00 AM EDT - 1 year ago

Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues

Sep 24, 2024, 7:00 AM EDT - 1 year ago

Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium

Aug 26, 2024, 7:00 AM EDT - 1 year ago

ACURX PHARMACEUTICALS ANNOUNCES PARTICIPATION AT THE H.C. Wainwright 26th Annual Global Investment Conference

Aug 9, 2024, 10:20 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. (ACXP) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 7:01 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business Update

Jul 17, 2024, 7:00 AM EDT - 1 year ago

USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome

Jul 16, 2024, 7:00 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business Update

Jul 15, 2024, 7:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference

May 15, 2024, 1:14 PM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. (ACXP) Q1 2024 Earnings Call Transcript

May 15, 2024, 9:00 AM EDT - 1 year ago

Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection

May 15, 2024, 7:00 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update

May 2, 2024, 7:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference

Vikingsstrade Oct. 3 at 5:51 PM

0 · Reply

knonaogn Oct. 3 at 4:03 PM

$ACXP Soon 60 to 180

0 · Reply

WallStVisions Oct. 3 at 1:06 PM

0 · Reply

NotBornYesterday Oct. 2 at 11:00 PM

Who do you think? Management uses $ACXP shareholders money to pay the Wainwright whorehouse underwriting fee everytime they dilute the shit out of the stock.

0 · Reply

1Spartantrade1 Oct. 2 at 6:25 PM

0 · Reply

ChicagoJoe20 Oct. 1 at 6:44 PM

$ACXP FU bacteria!

0 · Reply

knonaogn Oct. 1 at 5:31 PM

$ACXP $ACXP Acurx Pharmaceuticals Price Target Maintained With a $31.00/Share by HC Wainwright & Co

0 · Reply

NotBornYesterday Oct. 1 at 4:13 PM

$ACXP Good thing Wainwright's been accurate on the -90% move.

1 · Reply

ScrubaDubs Oct. 1 at 3:07 PM

$ACXP thar she blows

0 · Reply

prismmarketview Oct. 1 at 2:49 PM

0 · Reply

knonaogn Oct. 1 at 2:43 PM

$ACXP Coming soon $180 believe it or not

1 · Reply

VolcanicTrades Oct. 1 at 2:38 PM

$LIMN 🔥 and $ACXP 👀

0 · Reply

VolcanicTrades Sep. 30 at 10:07 PM

$ACXP keep an eye it from here $SPY low floater with news

0 · Reply

xolli Sep. 30 at 6:25 PM

$ACXP

1 · Reply

VolcanicTrades Sep. 30 at 4:50 PM

$ACXP low float setting up. Fresh PR + $31 price target

1 · Reply

ballyhooo Sep. 30 at 3:27 PM

$ACXP HC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $31 Price Target

0 · Reply

JarvisFlow Sep. 30 at 3:10 PM

HC Wainwright & Co. updates rating for Acurx Pharmaceuticals ( $ACXP ) to Buy, target set at 31.

0 · Reply

VolcanicTrades Sep. 30 at 2:22 PM

$ACXP low float with news $SPY

0 · Reply

ItTakesItAll Sep. 30 at 12:18 PM

$ACXP Adding great news.

0 · Reply

mebanks Sep. 30 at 11:38 AM

$ACXP, interesting news "Positive EMA opinion received for pediatric investigation plan (PIP)", "FDA QIDP and Fast-Track Designation already secured", "Potential for 11 years of marketing exclusivity in Europe", "Clear regulatory pathway established with both FDA and EMA", "Addresses significant unmet need in pediatric CDI treatment" ]

0 · Reply

ballyhooo Sep. 30 at 11:32 AM

$ACXP Acurx Announces Positive Opinion from EMA on Pediatric Investigation Plan for Ibezapolstat Use in Children with C. difficile Infection

0 · Reply

knonaogn Sep. 27 at 1:15 PM

$ACXP In my opinion this stock is worth investing $1000 here

1 · Reply

Market Cap	7.21M
Revenue (ttm)	0.00
Net Income (ttm)	-14.10M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	27,900
Avg Vol	82,747
Day's Range	N/A - N/A
Shares Out	1.59M
Stochastic %K	66%
Beta	-1.29
Analysts	Strong Sell
Price Target	$27.00